Pharmaceutical Executive, Jun 1, 2013 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Jun 1, 2013
Features
Adherence's New Players: Fresh Support from the Sidelines
By Clark Herman
New stakeholders, innovative technologies, and emergent synergies in government are combining to build fresh momentum behind the old issue of medication adherence. The question is will Big Pharma be flexible enough to keep pace with the changes?
Regeneron: New York State of Mind
By Ben Comer
Led by two New Yorkers with a mindset that marries novel scientific insights to the processing power of novel technologies, Regeneron's success is a revolutionary challenge to the industry status quo.
Unlocking the Key to Public Funding in Brazil
What is really driving decision making by the new Brazilian HTA agency? A look at appraisals issued in the first year.
Country Report
Country Report: Ireland
Ireland has been a pharma industry darling since the 1960s, when a then-newly established IDA targeted the sector as a strategic area for development. Today, the numbers are eyecatching. As reported by the IDA, nine out of the top 10 pharma companies in the world have substantial manufacturing operations in Ireland.
Column
Opening the Patent Box
By Julian Upton
Are the answers to the UK pharma sector's problems to be found in the government's new "Patent Box?"
Pharmacy Compounding: What's Ahead for Manufacturers
Compounders are under increased scrutiny following last year's spinal meningitis outbreak.
From Locked Box to Data Sphere
By Ben Comer
Project Data Sphere aims to liberate clinical trial data sets from industry and academic vaults, in an attempt to catalyze cancer research and discovery.
Finding Strategic Levers in the Supply Chain
Customer-focused supply-chain capabilities are becoming a more important part of a company's competitive advantage.
Washington Report: Innovation, Coverage, and Costs
By Jill Wechsler
The backlash against high prices for new medicines will impact research, patent exclusivity, and drug benefits.
When Gurus Get It Wrong
Despite their high status, management gurus aren't always on point when it comes to pharma, writes John Ansell.
From the Editor
Recognizing the Best
By William Looney
Getting patients to take their medicine on spec and on time is the challenge that never goes away—it's the deadweight baggage accompanying every industry innovation since the arrival of aspirin a century ago.

ADVERTISEMENT

Click here